The U.S. Food and Drug Administration (FDA) has accepted Rakuten Medical’s, Inc. application for to begin clinical studies of the company’s investigational new drug (IND) for patients with advanced squamous cell carcinoma or patients with neck and head squamous cell carcinoma. Advanced squamous cell and neck and head squamous cell carcinoma occur on the outer most layers of the skin and are the sixth most common type of cancers worldwide. The RM-1995 photoimmunotherapy treatment is a conjugate of photoactivatable dye and monoclonal antibody that work to target tumor-resident regulatory T cells (Tregs), cells that inhibit antitumor immune responses and promote tumor growth.  The company, Rakuten Medical, Inc., is a global clinical stage biotechnology company that focuses on cell-targeting investigational therapies, especially relating to carcinoma and tumor cells.

Read more here.